Details about László Gulácsi

Access statistics for papers by László Gulácsi.

Last updated 2023-05-06. Update your information in the RePEc Author Service.

Short-id: pgu509

Journal Articles

2014

1. Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective
   The European Journal of Health Economics, 2014, 15, (1), 73-82 View citations (5)
2. Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries
   The European Journal of Health Economics, 2014, 15, (1), 1-4
3. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries
   The European Journal of Health Economics, 2014, 15, (1), 35-43 View citations (7)
4. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
   The European Journal of Health Economics, 2014, 15, (1), 45-52
5. Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres
   The European Journal of Health Economics, 2014, 15, (1), 101-109 View citations (6)
6. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
   The European Journal of Health Economics, 2014, 15, (1), 53-64 View citations (2)
7. Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
   The European Journal of Health Economics, 2014, 15, (1), 129-129 View citations (7)
8. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
   The European Journal of Health Economics, 2014, 15, (1), 111-119 View citations (2)
9. HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain
   The European Journal of Health Economics, 2014, 15, (7), 675-680
10. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
    The European Journal of Health Economics, 2014, 15, (1), 13-25 View citations (9)
11. Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists
    The European Journal of Health Economics, 2014, 15, (1), 83-92 View citations (2)
12. The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study
    The European Journal of Health Economics, 2014, 15, (8), 853-867 View citations (4)
13. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries
    The European Journal of Health Economics, 2014, 15, (1), 27-34 View citations (2)
14. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
    The European Journal of Health Economics, 2014, 15, (1), 121-128 View citations (7)

2012

15. Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries
    Society and Economy, 2012, 34, (2), 221-240 View citations (2)
16. Health economics and health technology assessment in Central and Eastern Europe: a dose of reality
    The European Journal of Health Economics, 2012, 13, (5), 525-531 View citations (11)
17. Preferences of Hungarian consumers for quality, access and price attributes of health care services — result of a discrete choice experiment
    Society and Economy, 2012, 34, (2), 293-311 View citations (6)

2011

18. User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders
    Health Policy, 2011, 102, (2), 255-262 View citations (9)

2010

19. Future challenges for health economics and health technology assessment of biological drugs
    The European Journal of Health Economics, 2010, 11, (3), 235-238 View citations (1)
20. The disease burden of colorectal cancer in Hungary
    The European Journal of Health Economics, 2010, 10, (1), 35-40 View citations (2)

2009

21. Quality management and patient safety: Survey results from 102 Hungarian hospitals
    Health Policy, 2009, 90, (2-3), 175-180 View citations (2)

2007

22. The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
    The European Journal of Health Economics, 2007, 8, (2), 83-88 View citations (4)
23. Verseny az egészségügyben. Egyesült államokbeli és nyugat-európai példák
    (Competition in health care. US and West European examples)
    Közgazdasági Szemle (Economic Review - monthly of the Hungarian Academy of Sciences), 2007, LIV, (5), 480-498